Alzheimer’s & Dementia
News
Clinical Trial of Phosphodiesterase Inhibitor Begins for Treatment of Early Alzheimer’s Disease
Thursday, May 02, 2019—A phase 2 clinical trial has begun for a novel phosphodiesterase-4D (PDE4D) inhibitor, BPN14770 (Tetra Discovery Partners, Grand Rapids, MI)for potential improvement of i…
Humanized Antibody Targets Tau Protein in Alzheimer’s Disease
Tuesday, April 30, 2019—A Harvard Medical School study demonstrates that a humanized monoclonal antibody (TBL-100; TAU BIOLOGIC Corporation, New York, NY) targets C-terminally truncated tau (tauC3) f…
First Participant Dosed in Phase 2 Trial of Phosphodiesterase Inhibitor AR1001 for Alzheimer’s Disease
Friday, April 12, 2019—The first patient has been dosed in a phase 2 study evaluating safety and efficacy of AR1001 (AR1001; AriBio, San Diego, CA). A novel phosphodiesterase inhibitor, AR1001, is b…
Technology Has Potential to Halt Production of Mutated Protein in Huntington’s Disease and Spinocerebellar Ataxia
Monday, April 08, 2019—Early data supports a potential therapy for neurodegenerative diseases such as Huntington’s disease (HD) and spinocerebellar ataxia (SCA) that are caused by trinucleotid…
First Patients Dosed in Trial of Two-Drug Combination Therapy for Alzheimer’s Disease
Thursday, April 04, 2019—The first patients were dosed in a Phase 2 clinical trial to assess AMX0035 (Amylyx Pharmaceuticals, Inc., Cambridge, MA) in patients with Alzheimer’s disease. AMX0035 i…
Combination Drug Shows Promise for Treating Alzheimer’s-Associated Agitation
Friday, March 29, 2019—A combination of deudextromethorphan hydrobromide and quinidine sulfate (AVP-786; Avanir Pharmaceuticals, Alisa Viejo, CA) is being studied as potential treatment of moderate-…
Trofinetide Phase 2 Study Shows Safety and Clinically Relevant Improvement for Rett’s Syndrome
Wednesday, March 27, 2019—Positive results from a phase 2 randomized, placebo-controlled clinical trial (NCT02715115) of trofinetide (Acadia Pharmaceuticals, San Diego, CA; Neuren Pharmaceuticals, Melb…
FDA Finds Transcranial Magnetic Stimulation Plus Cognitive Training Exercise Safe, But Not Effective for Alzheimer's Disease
Tuesday, March 26, 2019—The Food and Drug Administration (FDA) Neurologic Devices Advisory Panel voted unanimously (14-0) not to recommend approval of transcranial magnetic stimulation (TMS) plus cog…
